Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion

Author:

Zhou Kuangguo1ORCID,Gong Duanhao1,He Cheng1,Xiao Min1,Zhang Meilan1,Huang Wei1

Affiliation:

1. Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

Abstract

AbstractOutcomes for patients with relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia (T‐ALL) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are dismal, with few available treatments. Recently, identification of cancer patients harboring neurotrophic tropomyosin receptor kinase (NTRK) gene fusions is constantly increasing, especially with the advent of NTRK inhibitors. However, the role of ETV6‐NTRK3 in T‐ALL has not been investigated. This case represented the first detailed report of T‐ALL patient harboring a cryptic ETV6‐NTRK3 fusion with an unfavorable prognosis, not only because of leukemia resistant to the standard multiagent chemotherapy but also early relapse after allo‐HSCT. Acquired EP300 mutation was found at relapse, which could explain the cause of recurrence and affect the follow‐up treatment. Combined targeted therapy like larotrectinib allied with pan‐targeted BCL‐2 inhibitor venetoclax, may be a potential maintenance treatment in R/R ETV6‐NTRK3 positive leukemia after allo‐HSCT. The leukemic clonal evolution might be revealed through transcriptome sequencing and overcome by drugs with universal targets. Our case demonstrated that both comprehensive profiling techniques (such as transcriptome sequencing, multiparameter flow cytometry, and digital droplet polymerase chain reaction) and a multimodality treatment strategy were critical for anticipating an early relapse and personalized therapy of R/R T‐cell leukemia.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3